Stocks scoring 0–25 beat the S&P 500
39.9% of the time over the next three months, since 2015.
How we measured this →
6
hedge funds
hold it · 2 added, 1 trimmed
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$524M
Industry
Diagnostics & Research
Sector
Healthcare
Exchange
NasdaqGS
About MYRIAD GENETICS INC
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic, a tumor test that determines homologous…
Who's behind the signal
Every informed buyer we can see on MYGN, across all three feeds.
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
MYRIAD GENETICS INC isn't in the top-10 model right now, but 6 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
6
Investors
0
New positions
2
Increasing
1
Decreasing
3
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to resetPinch to zoom · drag sideways to move through time
Return: High: Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to MYRIAD GENETICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell MYRIAD GENETICS INC or any security.